AMR in Focus: Mr Saransh Chaudhary’s Insights Across Media
Mr Saransh Chaudhary explores how antimicrobial innovation must move beyond conventional antibiotic discovery, highlighting safer drug design, translational research, targeted delivery and stronger innovation ecosystems.
Antimicrobial resistance (AMR) is reshaping the global healthcare landscape, creating an urgent need not only for new antibiotics but also for smarter approaches to antimicrobial innovation.
In recent media features, Mr Saransh Chaudhary, Executive Director, Venus Remedies Limited & CEO, Venus Medicine Research Centre (VMRC), has highlighted the scientific, commercial and translational challenges that must be addressed to build the next generation of antimicrobial solutions.
His perspectives, featured across Pharmaphorum and the European Biopharmaceutical Review (EBR), underline a common message: tackling AMR requires innovation that goes beyond conventional approaches.
What India can learn from global AMR innovation
In his Pharmaphorum article, “What India Can Learn from Kinvard Bio,” Mr Saransh Chaudhary examines the development model behind Kinvard Bio, a US-based antibiotic discovery company working on a new class of ribosome-targeting antibiotics.
Using Kinvard Bio as a case study, the article examines the wider ecosystem required to translate promising antibiotic science into therapies that can reach patients. It highlights the role of academic research, specialised investment, public-interest accelerators, and appropriate market incentives in supporting antibiotic innovation.
For India, Mr Saransh Chaudhary points to the opportunity to complement the country’s established pharmaceutical and scientific capabilities with stronger support for early-stage antibiotic discovery and development. Rather than simply adopting international models, the article emphasises the need for an ecosystem aligned with India’s own healthcare, procurement and market realities.
Moving Beyond Potency in Antimicrobial Design
His contribution to EBR takes the conversation further with the article, “Beyond Potency: Engineering Safer Antimicrobials for the Next Era of Antimicrobial Resistance Innovation.”
The article explores why the next breakthrough against AMR may not necessarily depend only on discovering new molecules. Redesigning and optimising existing therapies can also play an important role, particularly when clinicians are treating serious infections with limited therapeutic options.
It explores how conventional approaches can sometimes focus heavily on whether an antimicrobial can eliminate a pathogen, while factors such as toxicity, therapeutic exposure, and patient safety also influence clinical utility. The feature highlights emerging approaches including targeted delivery, drug repurposing, computational drug development and translational research, while emphasising the importance of integrating pharmacology, microbiology and formulation science early in the development process.
Strengthening AMR
With such discussions, Venus is rooting for its mission 2030: “To lead in antimicrobial resistance (AMR), a global threat to mankind, through science that is deep, differentiated, and built to stand when the world's existing arsenal fails.”
Venus continues to contribute to the wider conversation on how scientific innovation, safety, and ecosystem development can collectively strengthen the response to AMR. The challenge is not simply to discover more antimicrobials, but to create safer, scientifically differentiated, and economically sustainable solutions.
